Raymond James Financial Inc. Increases Stake in ANI Pharmaceuticals, Inc. $ANIP

Raymond James Financial Inc. increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 41.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 100,164 shares of the specialty pharmaceutical company’s stock after purchasing an additional 29,338 shares during the period. Raymond James Financial Inc. owned approximately 0.46% of ANI Pharmaceuticals worth $6,706,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. boosted its position in shares of ANI Pharmaceuticals by 34.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 4,930 shares of the specialty pharmaceutical company’s stock valued at $273,000 after buying an additional 1,256 shares during the period. Stifel Financial Corp raised its holdings in shares of ANI Pharmaceuticals by 20.4% in the fourth quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company’s stock worth $466,000 after buying an additional 1,425 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of ANI Pharmaceuticals by 20.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,288 shares of the specialty pharmaceutical company’s stock worth $403,000 after acquiring an additional 1,220 shares during the last quarter. Northern Trust Corp boosted its holdings in ANI Pharmaceuticals by 9.0% during the 4th quarter. Northern Trust Corp now owns 204,345 shares of the specialty pharmaceutical company’s stock valued at $11,296,000 after acquiring an additional 16,820 shares during the period. Finally, Ameriprise Financial Inc. grew its position in ANI Pharmaceuticals by 14.6% in the 4th quarter. Ameriprise Financial Inc. now owns 271,805 shares of the specialty pharmaceutical company’s stock valued at $15,025,000 after acquiring an additional 34,586 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 50,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $86.07, for a total value of $4,303,500.00. Following the completion of the sale, the chief financial officer directly owned 180,863 shares in the company, valued at approximately $15,566,878.41. This trade represents a 21.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Nikhil Lalwani sold 56,960 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $85.93, for a total transaction of $4,894,572.80. Following the transaction, the chief executive officer owned 411,219 shares in the company, valued at approximately $35,336,048.67. This trade represents a 12.17% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 405,538 shares of company stock worth $35,690,131 over the last ninety days. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.6%

NASDAQ:ANIP opened at $94.10 on Wednesday. The company’s 50-day simple moving average is $74.48 and its 200-day simple moving average is $67.55. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $95.60. The stock has a market capitalization of $2.04 billion, a P/E ratio of -122.21 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $211.37 million during the quarter, compared to analysts’ expectations of $187.18 million. During the same quarter in the prior year, the company posted $1.02 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 53.2% compared to the same quarter last year. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the subject of several research analyst reports. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Guggenheim reiterated a “buy” rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a “hold” rating in a research report on Monday, August 11th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.